跳至主要内容
临床试验/NCT06560307
NCT06560307招募中不适用

Examination of Programming with the Enterra® Therapy System in a Double-Blinded, Randomized, Prospective Study in the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation

Enterra Medical, Inc.12 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年7月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
12
主要终点
Change in Vomiting Absolute Frequency

研究概览

简要总结

The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures.

Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at monthly study visits.

Participants will be involved in the study for up to six months after treatment assignment.

Programming parameters in the study are within currently approved labeling.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Completed informed consent process with signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥18 or ≤70 years at time of Enterra® therapy implantation
  • Diagnosed with idiopathic or diabetic gastroparesis
  • Delayed solid-phase gastric emptying study (Eggbeaters™ test meal), completed within one year of patient enrollment in the study. Gastroparesis defined as > 60% retained at 2 hours and/or >10% retained at 4 hours
  • Investigator confirms normal endoscopy within one year of enrollment in the study
  • GCSI-DD score for nausea severity during the qualifying Baseline Period averaging 2.5 or more per week and vomiting averaging 5 or more episodes per week

排除标准

  • Post-surgical gastroparesis (e.g., fundoplication, Billroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator
  • History of pyloroplasty or pyloromyotomy or G-POEM
  • Pregnancy or breastfeeding at the time of consent, or intent to become pregnant during the study
  • Active H. pylori infection
  • Significant hepatic injury (elevated ALT, AST, bilirubin)
  • Metabolic, mechanical, or mucosal inflammatory causes that may explain GI symptoms such as gallbladder disease, small bowel bacterial overgrowth, IBS, inflammatory bowel disease, celiac disease, liver or pancreatic disease, or bowel obstruction
  • Patients with significant cardiac or cardiovascular disease, malignancy, or other conditions
  • Participation in other clinical studies
  • Use of narcotics more than three days per week or other drugs that may affect motility (e.g., Glucagon-like peptide 1 (GLP-1) agonist drug)
  • Cannabis and/or cannabinoid use that exceeds either:
  • Greater than 3 days of usage per week with 2 or less occurrences each day of use, or
  • Greater than 3 grams of total usage per week
  • Previous diagnosis or history of orthostatic intolerance, e.g., POTS, neurocardiogenic syncope, orthostatic hypotension
  • Subject experiences discomfort during stimulation assessment that cannot be tolerated
  • Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications
  • Evidence of a failed response to temporary gastric electrical stimulation

结局指标

主要结局

Change in Vomiting Absolute Frequency

时间窗: 3 Months

As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) weekly vomiting absolute frequency

Change in Nausea Severity Score

时间窗: 3 Months

As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) nausea severity score

次要结局

  • Change in Total Symptom Score(6 Months)
  • Change in Vomiting Absolute Frequency(1 Month)
  • Change in Quality of Life Score(6 Months)
  • Change in Nausea Severity Score(1 Month)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验

Study of Enhanced Programming Stimulation with the... | 临床试验